

# The Lab to Market Transition: Lessons from Faculty, Students, and Other Research Staff

Wednesday, February 16, 2022

[bu.edu/research/events](https://bu.edu/research/events)



# Agenda

- Welcome Remarks
- Presentations
  - Sean Anderson & Nicholas Vickers
  - Uros Kuzmanovic
  - Josh Javor
  - George Daaboul
- Q&A
- Innovator of the Year Award Presentation
- Closing Remarks

**Spinning out a real time tracking microscope**

**Sean Andersson**

Mechanical Engineering and Systems Engineering, College of Engineering

**Nic Vickers**

Mechanical Engineering, College of Engineering



## Who are we?



- **PhD Candidate, MechE (2022)**
- Expertise in optics and controls
- Veteran of 3 startups
- Interested in *technology adoption*



- **Professor, MechE and SE**
- Expertise in control, estimation, and robotics
- Interested in *technology transfer*

## What's our objective

### Nic

- Positive Impact on society
- Help Sean get *impact beyond publication* – people can't build it themselves easily
- Transition from PhD to post-PhD is a **good time to take risks**

### Sean

- Good time in my career to try something new
- Want to have an impact - *people don't use this technology if just in a paper*
- To support Nic as he goes through this- *he has passion here*


Our potential customers have questions they want to –  
but currently cannot -- answer!

Medical Researchers

Biophysicists

Pharmaceutical developers

“We are limited by the available tools. We spend too much energy on tool development.”  
Professor of Biophysics, Boise State University



“I am a biologist. I don’t want to build a microscope.”  
Group Leader, Netherlands Cancer Institute

## Barriers driving the need for new solutions

*Low resolution tools*

*Complex, bespoke instrumentation*

*Limited measurement modalities*


*Slow data acquisition*

Basic science breakthroughs!

New understanding of disease mechanisms!

New drugs


# Our Solution: Real-time direct tracking of individual biological macromolecules (with spectroscopic readout and contextual imaging)



“Tracking individual molecules allows us to see behavior that is obscured by the aggregate.”

Group Leader, NIH National Cancer Institute

# Where are we?





# What to convey, Lessons learned in this process so far

## Nic

- **File a technology disclosure** into the OTD before publishing. Without it, it will be harder to spin out a company.
- Participate in I-Corps Spark.

## Sean


- Put in that technology disclosure before you start publishing!! Many faculty just don't think of this; it's not in our typical path
- I-Corps is THERE. Take advantage of that and other great resources BU has to offer. Ask for help for the tech transfer team- that's what they are there for.
- Need a champion: I'm not giving up my day job...but Nic is!

## *From Academia to Startup*

# Uroš Kuzmanović

BME PhD Candidate / BioSens8 CEO & Co-Founder





Uroš Kuzmanović:  
*Passionate about driving societal impact through biotech*



BS Molecular & Cellular Biology  
Minor in Chemistry  
Myotonic Dystrophy Research

2009-2013



UIUC Team VP  
Piceatannol RNA Scaffold Engineer  
Lightbulb Moment!

2012



Research Fellow  
Yeast Metabolic Engineer

2013-2014



PhD Biomedical Engineering  
Novel Biosensor Development  
Impact through Biotech

2015-Present




CEO & Co-Founder

2020-Present



Boston University Office of Research



James Galagan:  
*Mining microbes to  
create impactful &  
novel technology*



WHITEHEAD INSTITUTE

Software Engineer  
Computational Biologist  
Center for Genome Research

1998-2005



Visiting Faculty  
Department of EE & CS

2008-2010



Associate Director  
Visiting Scientist  
Microbial Genome Analysis & Annotation

2005-2017



Associate Director  
System Biology

2008-2017



Professor  
Biomedical Engineering  
Biosensor Engineering

2008-Present




Boston University Office of Research

# What's my objective?



**U.S. per capita healthcare spending is almost twice the average of other wealthy countries**



SOURCE: Organisation for Economic Co-operation and Development, *OECD Health Statistics 2020*, July 2020.



NOTES: The five countries with the largest economies and those with both an above median GDP and GDP per capita, relative to all OECD countries, were included. Average does not include the U.S. Data are for 2019. Chart uses purchasing power parities to convert data into U.S. dollars.

© 2020 Peter G. Peterson Foundation

[PGPF.ORG](http://PGPF.ORG)



# What's the problem?




*Infertility is a growing national and global problem*



# What's the need?

Beachhead

Struggler



Name: Lisa  
 Age: 31  
 Status: trying to get pregnant for 6 months; more **proactive and using ovulation prediction tests** (LH strips) but frustrated by their lack of accuracy and inability to confirm the underlying problem. Might have PCOS -> no LH spike.

*>40 customer interviews*

- **Assess fertility → Check ovulation → PRG test**
  - Easier way to read test results → **reduce frustration, stress, and confusion**
  - Avoid peeing on a stick every day for 2 weeks → **reduce annoyance and degradation**
  - Blood-based test → **gain trust in test results**
  - Test at home → **gain privacy and convenience**
  - Quick time to result → **gain free time in their day**
  - Ability to share results easily → **gain comfort and support from community**



## What's the idea?

# MySens™




**Avoid anxiety, frustration & stress** by confirming ovulation **instantly, quantitatively & 4-10 days faster** than the competition

**Take comfort** in having to take only **1 test** and being able to **relay results** to their physician and support group

**Gain trust** by measuring from blood like the gold standard and get results from the **privacy** of their home




# Where are we?



Boston University Office of Research

# My learnings



Dave Coverly...

*technical*  
“The ~~sales~~ team did all they could, so I’d have to say the blame for that must fall on the consumer.”



# Spinout of Novel Magnetic Sensor Technology

# Josh Javor

Founder, Gradient Magnetics, LLC  
Postdoctoral Associate, Bishop Lab  
Department of Mechanical Engineering



## About the champions of this technology

- I am a developing scientific entrepreneur
- My **objective** is to bring technology from my PhD thesis to market, while learning valuable transferrable skills in entrepreneurship
- Professor Bishop's **objective** is to enable a dynamic future for students of his lab and to bring novel MEMS technologies to market.



**Josh Javor**  
*Founder*

- 10+ years developing electromagnetic sensing technology
- 5 years studying contractility of cardiac tissue
- PhD in Mechanical Engineering from Boston University



**David Bishop**  
*Technology Advisor*

- Led a team of 150+ people at Bell Labs in the commercialization of MEMS devices
- Over 23,000 citations and 50 issued patents
- Professor of Physics, MSE, BME, and Mechanical Engineering at Boston University



## The Need

- ER Physicians – Diagnosing emergency room chest pain will enable physicians to “rule out” emergencies and enable earlier and safer discharge of patients.
- Cardiologists - Predicting coronary artery disease outcomes will enable cardiologists to more accurately treat patients who fail stress tests and require cardiac catheterization.
- Channel
  - We will license or make and sell our product to existing companies (talking with two already) who serve physicians
  - Portable magnetic imaging will reach more MCG customers at a lower price.

# Our technology enables portable biomagnetic imaging

- Our IDEA is a new magnetic sensor...
  - Unshielded with intrinsic immunity to magnetic interference
  - Room temperature
  - Ambient pressure
  - Small package (~5mm side)
  - Low power requirements
- With our sensor, our customers will be able to expand into portable and wearable biomagnetic imaging markets, saving hospitals money and enhancing patients' quality of life.




# Our Venture Timeline

Funding

Technology

Business Development

We are here






# Our Venture Timeline

Funding  
Technology  
Business Development

We are here






# Our Venture Timeline

Funding  
Technology  
Business Development


We are here



# Our Venture Timeline

Funding  
Technology  
Business Development


We are here



# Our Venture Timeline

Funding  
Technology  
Business Development


We are here



# Our Venture Timeline

Funding  
Technology  
Business Development

We are here



## Primary Learning: Approaching the business with the scientific method can work for tech spinouts

- Some “hand-wavy” parts of business planning can feel like they lack credibility, especially when there is always a right and wrong answer - a ground truth – in science.
- However, your training as a PhD scientist can actually make you a very effective science entrepreneur.
- Whether your business viability would rely on 100 technical customers buying an expensive scientific tool, or 1M general users integrating a part of your technology into their daily life, you can do research on these items and prepare arguments to defend these estimates. At the end of the day, nothing should actually be “hand-wavy,” even though there may be a higher degree of uncertainty.
- To be successful here, you can apply the scientific method: develop hypotheses, methods for gathering information, and organize results to prove to yourself (and your future investors) that a need exists.

# Thank You



# George Daaboul

Co-founder and CSO  
NanoView Biosciences



# Who are we?



George Daaboul  
Biomedical Engineering Ph.D, 2013  
Mentor/PI: Selim Unlu  
Biomedical Engineering B.S, 2009  
Boston University



David Freedman co-founder  
Electrical and Computer Engineering Ph.D, 2010  
Biomedical Engineering Post-Doc, 2012 (PI: Selim Unlu)  
Boston University





# Objective

## Why a startup?

- Academia was not for me but wanted to pursue my own ideas.
- Attracted to independence
- Right time to take risk



Once you raise VC some of the independence is gone.


**The Need:** Our customer is a researcher (corporate or academic) looking to characterize composition of biological nanoparticles.

ExoView Platform provides multiple data points like size, protein composition and amount all in a single easy to use assay/measurement.



# NanoView's SP-IRIS<sup>1</sup> Technology Delivers Single Vesicle Characterization

Affinity capture technique with interferometric & fluorescent imaging



## 1 HIGHLY SPECIFIC SAMPLING

A coated ExoView chip is tiled with multiple antibodies to provide specific capture of vesicle surface markers

## 2 ENHANCED LABEL-FREE IMAGING

Bright field light is scattered & enhanced through patented interferometric microscopy of the bound vesicles

## 3 MULTIPLEXED ANALYSIS

Multiple surface and internal markers can be characterized & colocalized to yield single vesicle sensitivity through the addition of fluorescent antibodies

<sup>1</sup>Daaboul, et al., Scientific Reports. 2016

# Expediting the Current Workflow

ExoView® R100  
ExoView® Kits  
ExoViewer®  
Software

Current outdated industry workflow



ExoView workflow



## Advantages

- Only 35  $\mu$ l of sample needed
- Investigate any bodily fluid
- Measure sample, not biases from purification techniques
- Measure the concentration of subpopulations
- Measure size with high resolution
- Measure biomarkers on the surface and internal cargo

## RESULTS


Automation and parallel batch processing reduce hands-on time while increasing sample throughput producing single vesicle characterization of biomarkers



# Where is NanoView Now?



**NanoView**  
BIOSCIENCES



# Learning from Starting NanoView:

## Co-founder is key!

- Someone to lean on when things are tough
- Complimentary skills